Skip to Main Content

Paper Details

Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study.
Acta Oncol
9
2020
ALK, BRAF, DNA driver, EGFR, FGFR, PARP, PD-1, ROS1, cancer, colitis, colorectal cancer, end-stage cancer, mTOR, patient, patients, transient, tumor
Author NameAffiliation
Vigdis NygaardOslo University Hospital
Kjetil BoyeOslo University Hospital
Kjetil BoyeOslo University Hospital
Eivind HovigOslo University Hospital
Eivind HovigUniversity of Oslo
Eivind Hovig
Sigve NakkenOslo University Hospital
Sigve Nakken
Sigve NakkenUniversity of Oslo
Vessela N KristensenUniversity of Oslo
Vessela N KristensenOslo University Hospital
Ole Christian Lingj??rdeOslo University Hospital
Ole Christian Lingj??rdeUniversity of Oslo
Anne-Lise B??rresen-DaleUniversity of Oslo
Anne-Lise B??rresen-DaleOslo University Hospital
Anne-Lise B??rresen-DaleUniversity of Oslo
Anne-Lise B??rresen-DaleOslo University Hospital
  • 1 - 17

Datasets

Dataset
Description
Source Link
OncoMineCancer microarray data by gene or cancer typeLink
OncoMineCancer microarray data by gene or cancer typeLink
OncoMineCancer microarray data by gene or cancer typeLink
OncoMineCancer microarray data by gene or cancer typeLink
OncoMineCancer microarray data by gene or cancer typeLink
OncoMineCancer microarray data by gene or cancer typeLink
OncoMineCancer microarray data by gene or cancer typeLink
OncoMineCancer microarray data by gene or cancer typeLink
OncoMineCancer microarray data by gene or cancer typeLink
OncoMineCancer microarray data by gene or cancer typeLink
OncoMineCancer microarray data by gene or cancer typeLink
OncoMineCancer microarray data by gene or cancer typeLink
OncoMineCancer microarray data by gene or cancer typeLink
OncoMineCancer microarray data by gene or cancer typeLink
OncoMineCancer microarray data by gene or cancer typeLink
Release 1.2